The company manufactured and marketed pharmaceutical products across multiple therapeutic areas, with a focus on sterile injectables and infusions. Their products received approvals from regulatory bodies including US FDA, MHRA (UK), and TGA (Australia).
Therapeutic areas
OncologyInfectious DiseasesHematology
Modalities
Sterile injectablesInfusionsBiosimilars
Industry
Biotech
02
Drug pipeline
1 asset
propofol
Commercial
Indications
Anesthesia
03
Partnerships
Otsuka Pharmaceutical Factory Inc.Mitsui & Co. Ltd. (joint venture for Infusion business in India & Emerging Markets)Pfizer (strategic partnership for marketing and supply of sterile injectables)
Beyond the preview
Go deeper on Claris Lifesciences Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
Trial phase
Status
Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
Partners
Deal terms
Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
Funding rounds
Investors
Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
Peer companies
Targets
Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
Platforms
Patents
Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
Company news
Sources
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claris Lifesciences Limited.